Anixa Biosciences Enhances Global Patent Protection for Innovative Ovarian Cancer Vaccine

Strengthening Patents Worldwide: Anixa Biosciences' Breakthrough

Introduction

Anixa Biosciences, Inc., a leading biotechnology firm based in San Jose, California, has recently solidified its international patent protection for its innovative ovarian cancer vaccine technology. This development was marked by a Notice of Allowance from the Canadian Intellectual Property Office (CIPO), which supports their efforts in treating and preventing this challenging disease, particularly for high-risk populations.

The Significance of the Notice of Allowance

The allowance pertains to a patent that encompasses various methods for administering a groundbreaking immunogenic composition. This composition involves a nucleic acid encoding the anti-Müllerian hormone receptor 2 (AMHR2) polypeptide. By eliciting a targeted immune response against AMHR2, Anixa's approach aims to both prevent and treat ovarian cancer effectively.

This vaccine development is the result of collaborative efforts between Anixa, the respected Cleveland Clinic, and the National Cancer Institute (NCI). Designed to cater to populations at heightened risk—such as those with BRCA mutations or a familial history of ovarian cancer—this project carries immense promise for improving clinical outcomes in vulnerable groups.

Expanding International Coverage

With the addition of Canadian patent protection, Anixa now enhances its intellectual property portfolio, complementing previously established protections in the United States. The U.S. Patent Number 12,357,593, granted in July 2025, covers essential facets of the vaccine technology, emphasizing methods of stimulating an immune response targeting AMHR2. This comprehensive strategy emphasizes Anixa's commitment to fighting ovarian cancer on multiple fronts.

Commitments to Innovation

Dr. Amit Kumar, the Chairman and CEO of Anixa Biosciences, spoke about the importance of this recent development. He noted, "This Canadian Notice of Allowance further strengthens the international patent protection around our ovarian cancer vaccine program and supports the novelty of our AMHR2-targeted immunoprevention approach." Dr. Kumar emphasized that this allowance is a crucial part of a broader strategy to develop a versatile cancer vaccine platform, hinging on the utilization of retired-protein targets.

Additionally, the company reported a successful Phase 1 clinical trial for its breast cancer vaccine, showcasing positive outcomes funded by the Department of Defense in collaboration with Cleveland Clinic. This milestone further demonstrates the effectiveness of their unique vaccine technologies.

Understanding the Ovarian Cancer Vaccine

Anixa's vaccine targets AMHR2, a protein found in normal ovaries during the pre-menopausal stage, and that is also aberrantly expressed in specific ovarian cancer types. This innovative "retired" protein strategy focuses on training the immune system to identify and eradicate cells associated with ovarian cancer while sparing normal, healthy tissue.

A Broader Vision for Cancer Treatment

By broadening its patent landscape, Anixa is building a robust foundation for its cancer vaccine technologies. The firm is committed to exploring further clinical, regulatory, and strategic opportunities that align with its fight against cancer.

Anixa's therapeutic arsenal comprises liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in partnership with the Moffitt Cancer Center. This therapy incorporates a novel type of CAR-T technology, showcasing Anixa's commitment to pioneering advanced treatment modalities.

Conclusion

As Anixa Biosciences forges ahead, the company remains dedicated to its mission: combating cancer through innovative vaccine technologies and collaborations with premier research institutions. By securing international patent protection, Anixa not only solidifies its proprietary technologies but also reinforces its role as a leader in the fight against ovarian cancer.

To find out more about their ongoing projects and innovations, visit Anixa Biosciences.